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Background: Multiple trials suggest that high residual on-treatment platelet reactivity (HRPR) [Platelet Reactivity Units (PRU) ≥230] increases 
the incidence of major adverse cardiac events: death, myocardial infarction, target vessel revascularization and stent thrombosis (MACE). Data on 
routine real world testing is lacking
methods: 581 patients had PCI [371 acute coronary syndromes (ACS), 210 non-ACS] and platelet function testing after initial background aspirin 
and ≥ 600 mg of clopidogrel. For PRU at 12-24 hours < 230, maintenance 325 mg/day of aspirin and 75 or 150 mg/day of clopidogrel for 1 
week then 75 mg/day were continued unless followup testing at 1-3 weeks demonstrated HRPR. Most patients with initial HRPR were switched to 
prasugrel or ticagrelor with no further testing, as hyporesponse is rare; or clopidogrel 150 mg/day with repeat testing at 1-3 weeks. Continued HRPR 
on clopidogrel usually drove switching to prasugrel or ticagrelor unless contraindicated.
results: There were 225 (39%) HRPR (148 ACS vs. 77 non-ACS) and 356 (61%) responders (223 ACS vs. 133 non-ACS). MACE was similar between 
the two groups [7/225 (3.1%) vs. 6/356 (1.7%), respectively, p=0.27]. MACE for ACS patients was also similar between the two groups [5/148 
(3.4%) vs. 6/223 (2.7%), respectively, p=0.76]. Even after subdividing ACS to unstable angina (UA) and Non ST elevation MI (NSTEMI) vs. ST 
elevation MI (STEMI) MACE was similar for HRPR and responders [4/113 (3.5%) vs. 6/163 (3.7%), respectively, p=NS, for UA/NSTEMI and 1/35 
(2.8%) vs. 2/60 (3.3%), respectively, p=NS, for STEMI]. The 30 day incidence of stent thrombosis was only 1 in the HRPR group and was related to 
medication noncompliance.
conclusions: Adjusting anti-platelet therapy for ACS and non ACS patients, on the basis of VerifyNow testing results in low and equivalent MACE at 
30 days after PCI, for initial anti-platelet responders and HRPR patients switched to more effective therapy.
